Please login to the form below

Not currently logged in
Email:
Password:

Forster Communications and Cello Health launch sustainability service

New programme will drive innovation culture and enhance reputations

Powell-Smith and Taylor

L-R: Amanda Powell-Smith, CEO, Forster Communications and Jo Taylor, Corporate Affairs Head, Cello Health

Forster Communications and Cello Health have teamed up to offer the pharma industry a new sustainability service.

Launching today, ‘Sustainable Pharma Futures’ is a new programme that will help shape sustainability policies within companies.

Enhancing company reputation, driving innovation culture and productivity support are among the programme's objectives and are areas that are often “siloed internally and hidden from view”, says Forster Communications’ CEO Amanda Powell-Smith.

She said these areas are often “not joined up or realising its full value in driving positive change for the business, its stakeholders and society. We believe that the majority of pharmaceutical businesses are sitting on untapped potential and want to make sustainability good for society and good for business”.

According to a report by the Business and Sustainable Development Commission, achieving sustainable businesses could unlock a global market worth $12trillion and $1.8 trillion of that accounts for health and wellbeing.

However, business sustainability is not connected to work happening across the organisation such as employee wellbeing, product development and facilities management, says the companies.

Through communications, the new initiative aims to bring all of those areas together and identify opportunities that can be strengthened.

Cello will bring its experience of the pharma industry to the collaboration while Forster will offer its expertise in social change communications.

Cello Health Communications Corporate Affairs Head, Jo Taylor adds: “The market is changing – from commissioner buying habits to the fight for talent – and we have created Sustainable Pharma Futures to help organisations respond to this. The combined skills and experience of our two organisations give corporate affairs directors instant access to knowledge and insights on how they can build their role as ethical, responsible organisations who are making a difference. This is no longer a nice-to-do, it’s about securing a future for pharmaceutical businesses to operate in.”

19th February 2019

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...